Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction

Kozaková, Jana; Altay, Ayça; Ždı́mal, Vladimı́r; Mašková, Ludmila; Sonvico, Fabio; Quarta, Eride; Rossi, Alessandra; Buttini, Francesca; Colombo, Gaia

doi:10.1080/03639045.2019.1652636

Cited by 9 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of spray drying as a process for the obtention of the solid can be beneficial in the morphology of the particles, as already demonstrated by the spray-dried inhalation powder of colistimethate sodium for lung infections in CF [ 39 ]. Advantageous properties can be associated with the use of this technique such as the shape and diameter uniformity of the particles, which can provide good flowability, while the formation of hollow particles allows low-density structures, reducing the aerodynamic diameter and improving the aerosolization performances [ 40 , 41 ].…”

Section: Resultsmentioning

confidence: 99%

Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis

Magi,

de Lafuente,

Quarta

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Polyelectrolyte–drug complexes are interesting alternatives to improve unfavorable drug properties. Vancomycin (VAN) is an antimicrobial used in the treatment of methicillin-resistant Staphylococcus aureus pulmonary infections in patients with cystic fibrosis. It is generally administered intravenously with a high incidence of adverse side effects, which could be reduced by intrapulmonary administration. Currently, there are no commercially available inhalable formulations containing VAN. Thus, the present work focuses on the preparation and characterization of an ionic complex between hyaluronic acid (HA) and VAN with potential use in inhalable formulations. A particulate–solid HA-VAN25 complex was obtained by spray drying from an aqueous dispersion. FTIR spectroscopy and thermal analysis confirmed the ionic interaction between HA and VAN, while an amorphous diffraction pattern was observed by X-ray. The powder density, geometric size and morphology showed the suitable aerosolization and aerodynamic performance of the powder, indicating its capability of reaching the deep lung. An in vitro extended-release profile of VAN from the complex was obtained, exceeding 24 h. Microbiological assays against methicillin-resistant and -sensitive reference strains of Staphylococcus aureus showed that VAN preserves its antibacterial efficacy. In conclusion, HA-VAN25 exhibited interesting properties for the development of inhalable formulations with potential efficacy and safety advantages over conventional treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis

Magi,

de Lafuente,

Quarta

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The formation of agglomerates w noticeable, as it was also evident macroscopically, and it could also be seen structures one-inside-other particles in some cases. The use of spray drying as a process for the obtention of the solid can be beneficial the morphology of the particles, as already demonstrated by the spray-dried inhalati powder of colistimethate sodium for lung infections in CF [39]. Advantageous propert can be associated with the use of this technique such as the shape and diameter uniform of the particles, which can provide good flowability, while the formation of hollow par cles allows low-density structures, reducing the aerodynamic diameter and improving t aerosolization performances [40,41].…”

Section: Powder Characterizationmentioning

confidence: 88%

Novel Dry Powder of Hyaluronic Acid-Vancomycin Complex for Inhalation Useful on Pulmonary Infections Associated to Cystic Fibrosis

Magi,

De Lafuente,

Quarta

et al. 2024

Preprint

View full text Add to dashboard Cite

Polyelectrolyte-drug complexes are interesting alternatives to improve unfavourable drugs properties. Vancomycin (VAN) is an antimicrobial used in the treatment of methicillin-resistant Staphylococcus aureus pulmonary infections in patients with cystic fibrosis. It is generally administered intravenously with high incidence of adverse side effects, which could be reduced by intrapulmonary administration. Currently, there are no commercially available inhalable formulations containing VAN. Thus, the present work focuses on the preparation and characterization of an ionic complex between hyaluronic acid (HA) and VAN with potential use as inhalable formulations. Particulate-solid HA-VAN25 complex by spray drying from an aqueous dispersion was obtained. FTIR spectroscopy and thermal analysis confirmed the ionic interaction between HA and VAN, while an amorphous diffraction pattern by X-ray was observed. The powder density, geometric size and morphology showed a suitable aerosolization and aerodynamic performance of the powder, indicating the capability of reaching the deep lung. An in vitro extended-release profile of VAN from the complex was obtained, exceeding 24 hours. Microbiological assays against methicillin-resistant and -sensitive reference strains of Staphylococcus aureus, showed that VAN preserves its antibacterial efficacy. In conclusion, HA-VAN25 exhibited interesting properties for the development of inhalable formulations with potential efficacy and safety advantages over conventional treatment.

show abstract

“…The genetic dysfunction may translate into different defects of the protein, in any case ending up in bronchial obstruction that occurs due to the secretion and accumulation of a thick and sticky mucus in the airways. The accumulation of mucus creates the adequate conditions for bacterial colonization, which typically involves Pseudomonas aeruginosa and Staphilococcus aureus [84][85][86]. This justifies that cystic fibrosis therapy requires regular administration of antibiotics, apart from bronchodilators and mucolytics.…”

Section: Delivery Of Antibioticsmentioning

confidence: 99%

Multifunctional Nanocarriers for Lung Drug Delivery

Pontes

Grenha

2020

Nanomaterials

View full text Add to dashboard Cite

Nanocarriers have been increasingly proposed for lung drug delivery applications. The strategy of combining the intrinsic and more general advantages of the nanostructures with specificities that improve the therapeutic outcomes of particular clinical situations is frequent. These include the surface engineering of the carriers by means of altering the material structure (i.e., chemical modifications), the addition of specific ligands so that predefined targets are reached, or even the tuning of the carrier properties to respond to specific stimuli. The devised strategies are mainly directed at three distinct areas of lung drug delivery, encompassing the delivery of proteins and protein-based materials, either for local or systemic application, the delivery of antibiotics, and the delivery of anticancer drugs—the latter two comprising local delivery approaches. This review addresses the applications of nanocarriers aimed at lung drug delivery of active biological and pharmaceutical ingredients, focusing with particular interest on nanocarriers that exhibit multifunctional properties. A final section addresses the expectations regarding the future use of nanocarriers in the area.

show abstract

Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction

Cited by 9 publications

References 26 publications

Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis

Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis

Novel Dry Powder of Hyaluronic Acid-Vancomycin Complex for Inhalation Useful on Pulmonary Infections Associated to Cystic Fibrosis

Multifunctional Nanocarriers for Lung Drug Delivery

Contact Info

Product

Resources

About